Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification
- PMID: 38658794
- PMCID: PMC11669423
- DOI: 10.1038/s41588-024-01726-6
Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification
Abstract
CRISPR base editing screens enable analysis of disease-associated variants at scale; however, variable efficiency and precision confounds the assessment of variant-induced phenotypes. Here, we provide an integrated experimental and computational pipeline that improves estimation of variant effects in base editing screens. We use a reporter construct to measure guide RNA (gRNA) editing outcomes alongside their phenotypic consequences and introduce base editor screen analysis with activity normalization (BEAN), a Bayesian network that uses per-guide editing outcomes provided by the reporter and target site chromatin accessibility to estimate variant impacts. BEAN outperforms existing tools in variant effect quantification. We use BEAN to pinpoint common regulatory variants that alter low-density lipoprotein (LDL) uptake, implicating previously unreported genes. Additionally, through saturation base editing of LDLR, we accurately quantify missense variant pathogenicity that is consistent with measurements in UK Biobank patients and identify underlying structural mechanisms. This work provides a widely applicable approach to improve the power of base editing screens for disease-associated variant characterization.
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests
L.P. has financial interests in Edilytics and SeQure Dx. L.P.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.
Figures
















Update of
-
Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification.medRxiv [Preprint]. 2023 Sep 10:2023.09.08.23295253. doi: 10.1101/2023.09.08.23295253. medRxiv. 2023. Update in: Nat Genet. 2024 May;56(5):925-937. doi: 10.1038/s41588-024-01726-6. PMID: 37732177 Free PMC article. Updated. Preprint.
References
MeSH terms
Grants and funding
- 1R01GM143249/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- P30 ES010126/ES/NIEHS NIH HHS/United States
- R35 HG010717/HG/NHGRI NIH HHS/United States
- UM1HG012010/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- R01 GM143249/GM/NIGMS NIH HHS/United States
- 1R01HL164409/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- R01HG010372/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- 1R35HG010717-01/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- GNT1174405/Department of Health | National Health and Medical Research Council (NHMRC)
- R01 HL164409/HL/NHLBI NIH HHS/United States
- UM1 HG012010/HG/NHGRI NIH HHS/United States
- R56 HG012681/HG/NHGRI NIH HHS/United States
- R01 HG010372/HG/NHGRI NIH HHS/United States